Navigation Links
JHP Pharmaceuticals Announces Successful Completion of FDA and EMEA GMP Audits
Date:5/10/2010

PARSIPPANY, N.J., May 10 /PRNewswire/ -- JHP Pharmaceuticals' sterile manufacturing site based in Rochester, Michigan completed a successful GMP (Good Manufacturing Practices)/Pre Approval Audit by the U.S. Food and Drug Administration (FDA) drug division (CDER). This audit followed two successful GMP audits in 2009 including an audit by the FDA biologics division (CBER) and an audit by the European Medicines Agency (EMEA), which resulted in a continuance of the certificate of GMP compliance for the manufacturing site.

Stuart Hinchen, co-founder and President of JHP stated, "We are extremely pleased with the results of the recent audits of our Rochester, Michigan sterile injectable manufacturing facility. We understand the importance of compliant quality systems and we work diligently to maintain these systems to the highest global standards."

About JHP Pharmaceuticals, LLC

JHP Pharmaceuticals, headquartered in New Jersey, is a specialty pharmaceutical company that manufactures and sells sterile injectable products for the hospital market segment, and provides contract manufacturing of sterile injectable products for innovator pharmaceutical and biotech organizations. JHP markets 14 branded pharmaceutical products through its national sales and marketing infrastructure and contract manufactures both pharmaceutical and biotechnology products for small and large proprietary pharmaceutical and biotechnology companies. JHP employs more than 330 staff in the USA in its manufacturing, sales & marketing and corporate areas. JHP is a private company wholly owned by JHP Holdings, LLC. For more information, please visit www.jhppharma.com.


'/>"/>
SOURCE JHP Pharmaceuticals, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Oramed Pharmaceuticals Reports Results in Phase 2b Trial of Oral Insulin Administration to Type 2 Diabetes Patients
2. S*BIO and Onyx Pharmaceuticals Announce Expanded Development Collaboration for JAK2 Inhibitors
3. Amylin Pharmaceuticals to Present at the Deutsche Bank 35th Annual Healthcare Conference
4. Merrimack Pharmaceuticals Promotes William Sullivan to Vice President of Finance
5. Merrimack Pharmaceuticals Recognized for Innovative Talent Management in HR Executive Magazine's ‘Best HR Ideas for 2010' Issue
6. Shire Receives INTUNIV (TM) Paragraph IV Notice Letter From Teva Pharmaceuticals
7. OncoGenex Pharmaceuticals to Webcast Discussion of Financial Results for Fourth Quarter and Fiscal Year 2009
8. Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009
9. OncoGenex Pharmaceuticals to Present at RBC Capital Markets Healthcare Conference
10. APT Pharmaceuticals Completes Enrollment in Phase III for Inhaled Cyclosporine
11. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 Fourth Quarter and Full Year Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... , ... While the majority of commercial spectrophotometers and fluorometers use the z-dimension ... are higher end machines that use the more unconventional z-dimension of 20mm. Z-dimension ... bottom of the cuvette holder. , FireflySci has developed several Agilent flow cell ...
(Date:6/23/2016)... TORONTO , June 23, 2016 /PRNewswire/ - ... Ontario biotechnology company, Propellon ... the development and commercialization of a portfolio of ... cancers. Epigenetic targets such as WDR5 represent an ... contribute significantly in precision medicine for cancer patients. ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
Breaking Biology Technology:
(Date:6/2/2016)... , June 2, 2016 The Department ... has awarded the 44 million US Dollar project, for the ... Vehicle Plates including Personalization, Enrolment, and IT Infrastructure , ... in the production and implementation of Identity Management Solutions. Numerous ... however Decatur was selected for the ...
(Date:5/20/2016)...  VoiceIt is excited to announce its new ... By working together, VoiceIt and VoicePass will offer ... take slightly different approaches to voice biometrics, collaboration ... usability. Both ... "This marketing and technology partnership allows ...
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 ... subsidiary of Infosys (NYSE: INFY ), and Samsung ... global partnership that will provide end customers with a ... and payment services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ... for financial services, but it also plays a fundamental part ...
Breaking Biology News(10 mins):